Inventor · disambiguated record
Remon Van Geel
Also filed as: VAN GEEL REMON
13 granted patents·20 pending applications·170 citations·filing 2013–2025
90Inventor score
Top patents by PatentIndex Score
33 records- 0198US9504758B2Modified antibody, antibody-conjugate and process for the preparation thereofSYNAFFIX BV·Filed 2015·Granted Nov 29, 2016·65 cites·20 claims
- 0297US10266502B2Process for the cycloaddition of a halogenated 1,3-dipole compound with a (hetero)cycloalkyneSYNAFFIX BV·Filed 2015·Granted Apr 23, 2019·78 cites·15 claims
- 0391US11338043B2Antibody-conjugates with improved therapeutic index for targeting HER2 tumours and method for improving therapeutic index of antibody-conjugatesSYNAFFIX BV·Filed 2017·Granted May 24, 2022·8 cites·10 claims
- 0490US10072096B2Modified glycoprotein, protein-conjugate and process for the preparation thereofSYNAFFIX BV·Filed 2014·Granted Sep 11, 2018·9 cites·15 claims
- 0590US9988661B2Process for the modification of a glycoprotein using a glycosyltransferase that is or is derived from A β(1,4)-N-acetylgalactosaminyltransferaseSYNAFFIX BV·Filed 2016·Granted Jun 5, 2018·5 cites·11 claims
- 0686US2025177554A1Modified antibody, antibody-conjugate and process for the preparation thereofSYNAFFIX BV·Filed 2024·Application pending·0 cites
- 0783US9987373B2Modified glycoprotein, protein-conjugate and process for the preparation thereofSYNAFFIX BV·Filed 2014·Granted Jun 5, 2018·3 cites·19 claims
- 0882US11299759B2Process for the modification of a glycoprotein using a glycosyltransferase that is or is derived from a β(1,4)-n-acetylgalactosaminyltransferaseSYNAFFIX BV·Filed 2018·Granted Apr 12, 2022·1 cites·9 claims
- 0978US11951175B2Bioconjugates containing sulfamide linkers for use in treatmentSYNAFFIX BV·Filed 2017·Granted Apr 9, 2024·1 cites·21 claims
- 1074US12049656B2Process for the modification of a glycoprotein using a glycosyltransferase that is or is derived from a β(1,4)-n-acetylgalactosaminyltransferaseSYNAFFIX BV·Filed 2022·Granted Jul 30, 2024·0 cites·14 claims
- 1174US2024398971A1Bioconjugates containing sulfamide linkers for use in treatmentSYNAFFIX BV·Filed 2024·Application pending·0 cites
- 1271US12194107B2Modified antibody, antibody-conjugate and process for the preparation thereofSYNAFFIX BV·Filed 2020·Granted Jan 14, 2025·0 cites·22 claims
- 1370US2023127659A1Antibody-conjugates with improved therapeutic index for targeting her2 tumours and method for improving therapeutic index of antibody-conjugatesSYNAFFIX BV·Filed 2022·Application pending·0 cites
- 1468US11713453B2Enzymes for trimming of glycoproteinsSYNAFFIX BV·Filed 2020·Granted Aug 1, 2023·0 cites·18 claims
- 1565US12440573B2Antibody-conjugates for targeting of tumours expressing PTK7SYNAFFIX BV·Filed 2024·Granted Oct 14, 2025·0 cites·9 claims
- 1665US2025090679A1Antibody-conjugates for targeting of tumours expressing trop-2SYNAFFIX BV·Filed 2024·Application pending·0 cites
- 1763US2023226208A1Methods for the preparation of bioconjugatesSYNAFFIX BV·Filed 2023·Application pending·0 cites
- 1862US10745488B2Modified antibody, antibody-conjugate and process for the preparation thereofSYNAFFLIX BV·Filed 2013·Granted Aug 18, 2020·0 cites·35 claims
- 1961US2025082770A1Antibody-conjugates for targeting of tumours expressing carcinoembyronic antigenSYNAFFIX BV·Filed 2024·Application pending·0 cites
- 2061US2023190951A1Conjugates of antibodies an immune cell engagersSYNAFFIX BV·Filed 2022·Application pending·0 cites
- 2161US2023330245A1Antibody-exatecan conjugatesSYNAFFIX BV·Filed 2023·Application pending·0 cites
- 2260US2023355791A1Glycan-conjugated antibodies binding to fc-gamma receptorSYNAFFIX BV·Filed 2023·Application pending·0 cites
- 2359US2023364262A1Via cycloaddition bilaterally functionalized antibodiesSYNAFFIX BV·Filed 2022·Application pending·0 cites
- 2459US2019225706A1Modified glycoprotein, protein-conjugate and process for the preparation thereofSYNAFFIX BV·Filed 2018·Application pending·0 cites
- 2559US2023114866A1Via cycloaddition bilaterally functionalized antibodiesSYNAFFIX BV·Filed 2022·Application pending·0 cites
- 2659US2025262314A1Multifunctional antibodiesSYNAFFIX BV·Filed 2022·Application pending·0 cites
- 2759US2025205353A1Antibody-conjugates for targeting of tumours expressing nectin-4SYNAFFIX BV·Filed 2023·Application pending·0 cites
- 2858US2022096652A1Acetal-based cleavable linkersSYNAFFIX BV·Filed 2021·Application pending·0 cites
- 2957US2025367315A1Antibody-drug conjugates with masked pbd dimersSYNAFFIX BV·Filed 2025·Application pending·0 cites
- 3054US2016235861A1Glycoengineered antibody, antibody-conjugate and methods for their preparationSYNAFFIX BV·Filed 2014·Application pending·0 cites
- 3149US2016257764A1Glycoengineered antibody, antibody-conjugate and methods for their preparationSYNAFFIX BV·Filed 2014·Application pending·0 cites
- 3245US2025312474A1Anthracyclins and conjugates thereofSYNAFFIX BV·Filed 2025·Application pending·0 cites
- 3336US2017009266A1Process for the attachment of a galnac moiety comprising a (hetero)aryl group to a glcnac moiety, and product obtained therebySYNAFFIX BV·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Remon Van Geel files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →